Sugi Predict

Sugi Predict / Compounds / SCHEMBL478979

SCHEMBL478979

SCHEMBL478979

CS(=O)(=O)NC(=O)c1cccc(N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.49
▸ PBRM1 Q86U86 1/20 0.49
▸ KAT6A Q92794 1/20 0.48
▸ SCN9A Q15858 2/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ LMNA P02545 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ DDB1 Q16531 1/20 0.45
▸ CRBN Q96SW2 1/20 0.45
▸ SCN3A Q9NY46 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8306980 0.98 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2NPSR1HSD17B10
SCHEMBL17806411 0.84 SMN1; SMN2 (0.51) KDM4EALDH1A1SMN1; SMN2NPSR1HSD17B10
SCHEMBL9302340 0.83 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2NPSR1HSD17B10
SCHEMBL8544906 0.82 ALDH1A1 (0.49) KDM4EALDH1A1SMN1; SMN2NPSR1HSD17B10
SCHEMBL8543957 0.82 ALDH1A1 (0.49) KDM4EALDH1A1SMN1; SMN2NPSR1HSD17B10
SCHEMBL15695613 0.82 SCN9A (0.46) SCN9ALMNAPTPN1MEN1KMT2A
SCHEMBL280256 0.81 HDAC8 (0.68) SMN1; SMN2KAT6ASCN9ANPC1POLB
SCHEMBL13331743 0.81 KDM4E (0.65) KDM4EALDH1A1SCN9ANPC1POLB
SCHEMBL2159159 0.81 PKM (0.51) SCN9AMEN1KMT2ASCN3ACA1
SCHEMBL6159659 0.80 KDM4E (0.62) KDM4EALDH1A1SMN1; SMN2NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. 2012-11-08 — — US disclosed
EP-2410856-A1 DIAMINOPTERIDINE DERIVATIVES Biorelix, Inc. (US) 2012-02-01 — — EP disclosed
WO-2010110907-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. (US) 2010-09-30 — — WO disclosed
US-7384963-B2 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase GLAXO GROUP LIMITED (GB) 2008-06-10 — — US disclosed
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 — — US disclosed
EP-1435949-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 — — EP disclosed
EP-0807105-B1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO (JP) 2004-06-16 — — EP disclosed
WO-2003032986-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 — — WO disclosed
US-6239131-B1 WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. ZERIA PHARMACEUTICAL CO., LTD. (JP) 2001-05-29 — — US disclosed
US-5994368-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-11-30 — — US disclosed
WO-1996013485-A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-05-09 — — WO disclosed
US-5451582-A Cholecystokinins and gastrin receptor antagonists MERCK SHARP & DOHME LTD. (GB) 1995-09-19 — — US disclosed
US-5360802-A Antagonists of cholecystokinin and gastrin MERCK SHARPE & DOHME LTD. 1994-11-01 — — US disclosed
EP-0562855-A1 Carbapenem compounds as antibiotics ZENECA LIMITED (GB) 1993-09-29 — — EP disclosed
WO-1993017011-A1 BENZODIAZEPINE DERIVATIVES, AS CCK AND GASTRIN ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 1993-09-02 — — WO disclosed
CN-1074216-A Urea derivative GLAXO GROUP LTD (GB) 1993-07-14 — — CN disclosed
US-5220018-A Benzodiazepine derivatives MERCK & CO., INC. (US) 1993-06-15 — — US disclosed
EP-0538945-A1 Benzodiazepine derivatives, and their use as antagonists of gastrin and/or cholecystokinin GLAXO GROUP LIMITED (GB) 1993-04-28 — — EP disclosed
EP-0514133-A1 Benzodiazepine derivatives, compositions containing them and their use in therapy MERCK SHARP & DOHME LTD. (GB) 1992-11-19 — — EP disclosed
EP-0508796-A1 Cholecystokinin antagonists MERCK & CO. INC. (US) 1992-10-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES MPO, AOC1, DCTD KDM4E 3886/4885ALDH1A1 3124/4885SMN1; SMN2 3511/4885
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors MAPK1, MAPK3, MAPK6 KDM4E 420/4885ALDH1A1 1805/4885SMN1; SMN2 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.